Tweet
Dr. Burt is leading the MIST clinical trial at Northwestern and is highly respected. In his opinion piece just published in Multiple Sclerosis Journal, he debates the types of HSCT treatments for MS, the misconception of danger in particular with non-myeloablative regimens, the powerful effects (the only treatment to show improvements of >1 EDSS points), and the reasoning for doing this procedure early while there is still inflammation (relapse remitting phase). Interesting reading. He is less excited about BEAM because of the risk, but it may be more potent. Half a dozen of one....
Autologous hematopoietic stem cell transplantation for multiple sclerosis – if confused or hesitant, remember: ‘Treat with standard immune suppressive drugs and if no inflammation, no response’
Richard K Burt1
Roumen Balabanov2
Julio Voltarelli3
Amilton Barreira4
Joachim Burman5
1Division of Immunotherapy, Department of Medicine, Northwestern University Feinberg School of Medicine Chicago, USA
2Department of Neurology, Rush University Medical Center, Chicago, USA
3Hemocentro Regional-RP, Department of Neurosciences, University of Sao Paulo, Brazil
4Division of Neurology, Department of Neurosciences, University of Sao Paulo, Brazil
5Department of Neuroscience/Neurology, Uppsala University, Sweden
In 1995 autologous hematopoietic stem cell transplantation (HSCT) was first suggested in the medical literature as a treatment for multiple sclerosis (MS).At that time, HSCT was viewed as a high-risk procedure to be utilized as a salvage therapy in late progressive disease, a perception that still lingers to this day.
http://msj.sagepub.com/content/18/6/772.full?etoc
Richard K Burt1
Roumen Balabanov2
Julio Voltarelli3
Amilton Barreira4
Joachim Burman5
1Division of Immunotherapy, Department of Medicine, Northwestern University Feinberg School of Medicine Chicago, USA
2Department of Neurology, Rush University Medical Center, Chicago, USA
3Hemocentro Regional-RP, Department of Neurosciences, University of Sao Paulo, Brazil
4Division of Neurology, Department of Neurosciences, University of Sao Paulo, Brazil
5Department of Neuroscience/Neurology, Uppsala University, Sweden
In 1995 autologous hematopoietic stem cell transplantation (HSCT) was first suggested in the medical literature as a treatment for multiple sclerosis (MS).At that time, HSCT was viewed as a high-risk procedure to be utilized as a salvage therapy in late progressive disease, a perception that still lingers to this day.
http://msj.sagepub.com/content/18/6/772.full?etoc